Scholarlink

Background <p>Evidence on the cardiovascular benefits of combining empagliflozin with glucagon-like peptide-1 receptor agonists (GLP-1RA) is limited, derived primarily from indirect comparisons or subgroup analyses of cardiovascular outcome trials.</p> Methods <p>We conducted a cohort study emulating two comparative effectiveness trials using US healthcare databases (2013–2022), including federal Medicare and commercial claims data (Optum Clinformatics and MarketScan). Among adults with type 2 diabetes in routine care, we compared cardiovascular outcomes in patients initiating: (i) empagliflozin first, followed by augmentation with either GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i), and (ii) GLP-1RA first, followed by augmentation with either empagliflozin or sulfonylureas. Primary outcomes were modified major adverse cardiovascular events (MACE; composite of myocardial infarction, stroke, and all-cause mortality) and a composite of hospitalization for heart failure (HHF) or all-cause mortality. We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years with 95% confidence intervals (CI), adjusting for over 130 baseline covariates using propensity score matching weights.</p> Results <p>Compared with empagliflozin-DPP-4i initiators, empagliflozin-GLP-1RA was associated with lower risk of MACE [HR: 0.81 (95% CI: 0.67, 0.97); RD: -3.7 (-7.1, -0.2)] and lower HHF-mortality [HR: 0.61 (0.48, 0.77); RD: -6.6 (-9.3, -3.9)]. Compared with the GLP-1RA-sulfonylurea combination, the GLP-1RA-empagliflozin combination had lower risks of MACE [HR: 0.68 (0.56, 0.81); RD: -5.3 (-7.9, -2.6)] and HHF-mortality [HR: 0.62 (0.51, 0.76); RD: -3.7 (-6.1, -1.8)].</p> Conclusions <p>In US clinical practice, adding GLP-1RA to empagliflozin was associated with lower risks of MACE and HHF-mortality compared with adding DPP-4i. Among GLP-1RA initiators, adding empagliflozin was associated with lower cardiovascular risk than adding sulfonylureas, supporting potential additive cardiovascular benefits of GLP-1RA-empagliflozin combination therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月12日

查看全文
  • Phyo T. Htoo,
  • Hanseul Cho,
  • Julie M. Paik,
  • Katsiaryna Bykov,
  • Brendan M. Everett,
  • Robert J. Glynn,
  • Christina Shay,
  • Niklas Schmedt,
  • Deborah J. Wexler,
  • Elisabetta Patorno

摘要

Background

Evidence on the cardiovascular benefits of combining empagliflozin with glucagon-like peptide-1 receptor agonists (GLP-1RA) is limited, derived primarily from indirect comparisons or subgroup analyses of cardiovascular outcome trials.

Methods

We conducted a cohort study emulating two comparative effectiveness trials using US healthcare databases (2013–2022), including federal Medicare and commercial claims data (Optum Clinformatics and MarketScan). Among adults with type 2 diabetes in routine care, we compared cardiovascular outcomes in patients initiating: (i) empagliflozin first, followed by augmentation with either GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i), and (ii) GLP-1RA first, followed by augmentation with either empagliflozin or sulfonylureas. Primary outcomes were modified major adverse cardiovascular events (MACE; composite of myocardial infarction, stroke, and all-cause mortality) and a composite of hospitalization for heart failure (HHF) or all-cause mortality. We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years with 95% confidence intervals (CI), adjusting for over 130 baseline covariates using propensity score matching weights.

Results

Compared with empagliflozin-DPP-4i initiators, empagliflozin-GLP-1RA was associated with lower risk of MACE [HR: 0.81 (95% CI: 0.67, 0.97); RD: -3.7 (-7.1, -0.2)] and lower HHF-mortality [HR: 0.61 (0.48, 0.77); RD: -6.6 (-9.3, -3.9)]. Compared with the GLP-1RA-sulfonylurea combination, the GLP-1RA-empagliflozin combination had lower risks of MACE [HR: 0.68 (0.56, 0.81); RD: -5.3 (-7.9, -2.6)] and HHF-mortality [HR: 0.62 (0.51, 0.76); RD: -3.7 (-6.1, -1.8)].

Conclusions

In US clinical practice, adding GLP-1RA to empagliflozin was associated with lower risks of MACE and HHF-mortality compared with adding DPP-4i. Among GLP-1RA initiators, adding empagliflozin was associated with lower cardiovascular risk than adding sulfonylureas, supporting potential additive cardiovascular benefits of GLP-1RA-empagliflozin combination therapy.